Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature

Fluoropyrimidine-based chemotherapies are widely used to treat gastrointestinal tract, head and neck, and breast carcinomas. Severe toxicities mostly impact rapidly dividing cell lines and can occur due to the partial or complete deficiency in dihydropyrimidine dehydrogenase (DPD) catabolism. Since...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodroj, K., Barthelemy, D., Lega, J.-C., Grenet, G., Gagnieu, M.-C., Walter, T., Guitton, J., Payen-Gay, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095125/
https://www.ncbi.nlm.nih.gov/pubmed/33895696
http://dx.doi.org/10.1016/j.esmoop.2021.100125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095125/
https://www.ncbi.nlm.nih.gov/pubmed/33895696
http://dx.doi.org/10.1016/j.esmoop.2021.100125

Ejemplares similares